questionsmedicales.fr
Facteurs biologiques
Pigments biologiques
Pigments biliaires
Bilirubine
Bilirubine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Intersectoral Collaboration
Diagnostic
5
Bilirubine
Analyse sanguine
Tests de laboratoire
Fonction hépatique
Maladies hépatiques
Obstruction biliaire
Symptômes
5
Hyperbilirubinémie
Jaunisse
Maladies hépatiques
Symptômes
Prévention
5
Ictère néonatal
Prévention
Examens médicaux
Fonction hépatique
Maladies hépatiques
Prévention
Alimentation
Santé du foie
Traitements
5
Hyperbilirubinémie
Traitement
Transfusions sanguines
Anémie hémolytique
Corticostéroïdes
Bilirubine
Photothérapie
Ictère néonatal
Chirurgie
Obstruction biliaire
Complications
5
Complications
Lésions hépatiques
Hyperbilirubinémie
Dommages cérébraux
Obstruction biliaire
Infections
Grossesse
Hyperbilirubinémie
Cirrhose
Insuffisance hépatique
Facteurs de risque
5
Facteurs de risque
Maladies hépatiques
Alcoolisme
Hyperbilirubinémie
Infections virales
Hépatite
Surpoids
Maladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bilirubine : Questions médicales les plus fréquentes",
"headline": "Bilirubine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bilirubine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-22",
"dateModified": "2026-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bilirubine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pigments biliaires",
"url": "https://questionsmedicales.fr/mesh/D001654",
"about": {
"@type": "MedicalCondition",
"name": "Pigments biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001654",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Biliverdine",
"alternateName": "Biliverdine",
"url": "https://questionsmedicales.fr/mesh/D001664",
"about": {
"@type": "MedicalCondition",
"name": "Biliverdine",
"code": {
"@type": "MedicalCode",
"code": "D001664",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193.184.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Bilirubine",
"alternateName": "Bilirubin",
"code": {
"@type": "MedicalCode",
"code": "D001663",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Claudio Tiribelli",
"url": "https://questionsmedicales.fr/author/Claudio%20Tiribelli",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Libor Vítek",
"url": "https://questionsmedicales.fr/author/Libor%20V%C3%ADtek",
"affiliation": {
"@type": "Organization",
"name": "4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic."
}
},
{
"@type": "Person",
"name": "Silvia Gazzin",
"url": "https://questionsmedicales.fr/author/Silvia%20Gazzin",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Sri Jayanti",
"url": "https://questionsmedicales.fr/author/Sri%20Jayanti",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Kosuke Koyano",
"url": "https://questionsmedicales.fr/author/Kosuke%20Koyano",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[Healthcare for people with rare diseases: recommendations for successful intersectoral collaboration].",
"datePublished": "2023-06-13",
"url": "https://questionsmedicales.fr/article/37311814",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00103-023-03719-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intersectoral collaboration in the COVID-19 response in Latin America and the Caribbean.",
"datePublished": "2024-08-06",
"url": "https://questionsmedicales.fr/article/39107792",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12939-024-02233-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessing capacities to strengthen intersectoral collaboration in Territorial Public Health Councils in the Republic of Moldova.",
"datePublished": "2024-05-30",
"url": "https://questionsmedicales.fr/article/38814932",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0303821"
}
},
{
"@type": "ScholarlyArticle",
"name": "Patient experiences of interprofessional collaboration and intersectoral communication in rare disease healthcare in Germany - a mixed-methods study.",
"datePublished": "2024-05-13",
"url": "https://questionsmedicales.fr/article/38741100",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13023-024-03207-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Stakeholder views on work participation for workers with depression and intersectoral collaboration in depression care: a focus group study with a salutogenic perspective.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37526348",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/02813432.2023.2238019"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pigments biologiques",
"item": "https://questionsmedicales.fr/mesh/D010860"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pigments biliaires",
"item": "https://questionsmedicales.fr/mesh/D001654"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bilirubine",
"item": "https://questionsmedicales.fr/mesh/D001663"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bilirubine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bilirubine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-26",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bilirubine",
"description": "Comment mesurer le taux de bilirubine ?\nQuels tests diagnostiques sont utilisés ?\nQu'indique un taux élevé de bilirubine ?\nQuelle est la différence entre bilirubine directe et indirecte ?\nQuels symptômes peuvent nécessiter un test de bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Intersectoral+Collaboration#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bilirubine",
"description": "Quels sont les symptômes d'une hyperbilirubinémie ?\nLa bilirubine affecte-t-elle la peau ?\nQuels signes indiquent une maladie hépatique ?\nLa bilirubine peut-elle causer des démangeaisons ?\nComment la bilirubine affecte-t-elle l'urine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Intersectoral+Collaboration#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bilirubine",
"description": "Comment prévenir l'ictère néonatal ?\nQuels examens réguliers sont recommandés ?\nComment éviter les maladies hépatiques ?\nLes vaccinations sont-elles importantes ?\nComment une alimentation saine aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Intersectoral+Collaboration#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bilirubine",
"description": "Comment traiter une hyperbilirubinémie ?\nLes transfusions sanguines sont-elles nécessaires ?\nQuels médicaments peuvent réduire la bilirubine ?\nLa photothérapie est-elle efficace ?\nQuand envisager une chirurgie pour la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Intersectoral+Collaboration#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bilirubine",
"description": "Quelles complications peuvent survenir avec une bilirubine élevée ?\nL'hyperbilirubinémie peut-elle causer des dommages cérébraux ?\nQuels sont les risques d'une obstruction biliaire ?\nComment l'hyperbilirubinémie affecte-t-elle la grossesse ?\nQuelles sont les conséquences d'une maladie hépatique avancée ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Intersectoral+Collaboration#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bilirubine",
"description": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?\nL'alcoolisme est-il un facteur de risque ?\nLes infections virales influencent-elles la bilirubine ?\nLe surpoids est-il un facteur de risque ?\nLes médicaments peuvent-ils affecter la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Intersectoral+Collaboration#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le taux de bilirubine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le taux de bilirubine est mesuré par une analyse sanguine."
}
},
{
"@type": "Question",
"name": "Quels tests diagnostiques sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la bilirubine totale et directe, ainsi que des tests hépatiques."
}
},
{
"@type": "Question",
"name": "Qu'indique un taux élevé de bilirubine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé peut indiquer une maladie hépatique, une obstruction biliaire ou une anémie."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre bilirubine directe et indirecte ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bilirubine directe est soluble dans l'eau, tandis que l'indirecte ne l'est pas."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent nécessiter un test de bilirubine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme jaunisse, fatigue ou douleurs abdominales peuvent nécessiter un test."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hyperbilirubinémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, urine foncée, selles claires et démangeaisons."
}
},
{
"@type": "Question",
"name": "La bilirubine affecte-t-elle la peau ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un excès de bilirubine peut provoquer un jaunissement de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie hépatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la fatigue, l'ictère et des douleurs abdominales peuvent indiquer une maladie hépatique."
}
},
{
"@type": "Question",
"name": "La bilirubine peut-elle causer des démangeaisons ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de bilirubine peut provoquer des démangeaisons cutanées."
}
},
{
"@type": "Question",
"name": "Comment la bilirubine affecte-t-elle l'urine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé de bilirubine peut rendre l'urine foncée, semblable à celle du thé."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'ictère néonatal ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'ictère néonatal peut être prévenu par une surveillance attentive des nouveau-nés et une alimentation adéquate."
}
},
{
"@type": "Question",
"name": "Quels examens réguliers sont recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction hépatique sont recommandés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Comment éviter les maladies hépatiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'alcool, maintenir un poids santé et se faire vacciner contre l'hépatite aide à prévenir les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre l'hépatite A et B sont cruciales pour prévenir les infections hépatiques."
}
},
{
"@type": "Question",
"name": "Comment une alimentation saine aide-t-elle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée aide à maintenir la santé du foie et à prévenir l'accumulation de bilirubine."
}
},
{
"@type": "Question",
"name": "Comment traiter une hyperbilirubinémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la cause sous-jacente, comme des médicaments ou une intervention chirurgicale."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas d'anémie hémolytique, des transfusions peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent réduire la bilirubine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les corticostéroïdes peuvent être utilisés pour traiter certaines conditions."
}
},
{
"@type": "Question",
"name": "La photothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photothérapie est souvent utilisée pour traiter l'ictère néonatal en réduisant la bilirubine."
}
},
{
"@type": "Question",
"name": "Quand envisager une chirurgie pour la bilirubine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être envisagée en cas d'obstruction biliaire ou de maladies hépatiques graves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une bilirubine élevée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des lésions hépatiques, des troubles neurologiques et des infections."
}
},
{
"@type": "Question",
"name": "L'hyperbilirubinémie peut-elle causer des dommages cérébraux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperbilirubinémie sévère peut entraîner des dommages cérébraux, surtout chez les nouveau-nés."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une obstruction biliaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des douleurs abdominales et des lésions hépatiques."
}
},
{
"@type": "Question",
"name": "Comment l'hyperbilirubinémie affecte-t-elle la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des complications pour la mère et le fœtus, nécessitant une surveillance étroite."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une maladie hépatique avancée ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies hépatiques, des infections et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'alcoolisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'alcoolisme peut endommager le foie et augmenter le risque d'hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les infections virales influencent-elles la bilirubine ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections comme l'hépatite peuvent augmenter les niveaux de bilirubine."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut contribuer à des maladies hépatiques et à une hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils affecter la bilirubine ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec le métabolisme de la bilirubine et augmenter ses niveaux."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2026
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
4 publications dans cette catégorie
Affiliations :
4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Publications dans "Bilirubine" :
4 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Faculty of Medicine, University of Hasanuddin, Makassar 90245, Indonesia.
Molecular Biomedicine Ph.D. Program, Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neonatology Department, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neurology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, 34139 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Italian Liver Fondation, Bldg. Q-AREA Science Park Basovizza, SS14, km. 163,5, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Hepatic Surgery and Liver transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Bilirubine" :
Rare diseases often present complex symptoms and usually require intersectoral collaboration during diagnostic and therapeutic processes involving inpatient and outpatient care. Hence, smooth interfac...
Using quantitative and qualitative methods, multiple perspectives (primary physicians, expert centers of rare diseases, patients, parents) were assessed. Additionally, two expert workshops were conduc...
Based on findings from our data, we formulated 28 recommendations in the following areas: (1) networking between primary physicians and expert centers, (2) intersections within the expert centers, (3)...
Our recommendations provide a basis for a working management of intersectoral care in rare diseases. As the recommendations are based on broad data including multiple perspectives, external validity a...
World Health Organization (WHO) / Pan American Health Organization (PAHO) encouraged the utilization of whole-of-society and whole-of-government strategic approaches to increase countries' resilience ...
The government of the Republic of Moldova, endorsed the principle of Health in All Policies (HiAP) through its health sector reforms to address the rising burden of non-communicable diseases and healt...
A mixed-method approach, using qualitative and quantitative techniques, was used to compare the perceptions of all TPHC members (n = 112) and invitees (n = 53) to council meetings from 10 districts co...
Half of all TPHC members, including 75% from groups with a non-medical background, did not attend a public health course within the last three years. Overall, groups with a medical background were mor...
HiAP implementation was found to be suboptimal with insufficient capacity at local level. TPHC members' ability to deal with public health issues were severely impaired by a general lack of knowledge ...
Rare diseases are often complex, chronic and many of them life-shortening. In Germany, healthcare for rare diseases is organized in expert centers for rare diseases. Most patients additionally have re...
In total 299 individuals of whom 176 were patients and 123 were caregivers to pediatric patients participated in a survey using a questionnaire comprising several instruments and constructs. Fifty par...
Our findings indicate the high relevance of transferring affected patients to specialized care as fast as possible to provide best medical treatment and increase patient satisfaction. Intersectoral co...
To explore how stakeholders in depression care view intersectoral collaboration and work participation for workers with depression....
Focus group study applying reflexive thematic analysis using a salutogenic perspective....
We conducted seven focus group interviews in six different regions in Norway with 39 participants (28 women); three groups consisted of general practitioners (GPs), two of psychologists and psychiatri...
Stakeholders considered work participation salutary for most workers with depression, given the right conditions (e.g. manageable work accommodations and accepting and inclusive workplaces). They also...
Stakeholders highlighted the salutary properties of work participation for workers with depression under the right conditions. Intersectoral collaboration could support these conditions by sharing ins...
Western Australia has one of the highest rates of Aboriginal children entering out-of-home care in Australia. Kinship care is the preferred culturally safe out-of-home care option for Aboriginal child...
Constructivist grounded theory guided this research involving 55 semi-structured interviews and four focus group discussions with Aboriginal primary healthcare workers. The research was guided by Indi...
Key themes identified around intersectoral collaboration challenges were communication, including information sharing and interagency meetings, and the relationship with the government sector, includi...
This study addresses a significant research gap concerning out-of-home care, kinship care, and intersectoral collaboration in an Australian Aboriginal context. Findings highlighted the need to review ...
Mental and neuropsychological disorders make up approximately 14% of the total health burden globally, with 80% of the affected living in low- and middle-income countries (LMICs) of whom 90% cannot ac...
This is a pragmatic mixed-methods hybrid Type II implementation-effectiveness study utilizing a co-design approach. The main study utilize a stepped-wedged trial design with six starting sequences, ra...
Based on the results, we will develop sustainable and scalable implementation advice on mental health promotion and draft implementation guidelines in line with current WHO guidelines. This project wi...
ClinicalTrials, NCT06275672, 28.12.2023, retrospectively registered....
Many people face problems about physical, mental, and social dimensions of health, and may have complex needs. They often experience a mismatch between their needs and the ability of the healthcare sy...
The interdependent and intersecting nature of the Sustainable Development Goals (SDGs) require collaboration across government sectors, and it is likely that departments with few past interactions wil...
Interviews [n=17] with senior public servants leading SDG work in nine departments in the federal government of Canada were conducted to elicit information about issues affecting how departments engag...
The mechanisms for successful IA were identified as facilitative governance, leadership by a central coordinating office, supportive staff, flexible and clear reporting structures, adequate resources,...
IA is becoming a normal way of working on problems that cross otherwise separate government accountabilities. The success of these collaborations can be impacted by contextual factors beyond any one d...
Intersectoral collaboration is a collaborative approach between the health sectors and other sectors to address the interdependent nature of the social determinants of health associated with chronic d...
This protocol is developed by the Arksey and O'Malley (2005) framework for scoping reviews and the Levac...
This review does not require ethical approval. The results will be disseminated through a peer-reviewed publication and presentations to stakeholders....